AbbVie Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Earnings
| years ended December 31 (in millions, except per share data) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net revenues | $54,318 | $58,054 | $56,197 |
| Cost of products sold | 20,415 | 17,414 | 17,446 |
| Selling, general and administrative | 12,872 | 15,260 | 12,349 |
| Research and development | 7,675 | 6,510 | 6,922 |
| Acquired IPR&D and milestones | 778 | 697 | 1,124 |
| Other operating expense (income), net | (179) | 56 | 432 |
| Total operating costs and expenses | 41,561 | 39,937 | 38,273 |
| Operating earnings | 12,757 | 18,117 | 17,924 |
| Interest expense, net | 1,684 | 2,044 | 2,384 |
| Net foreign exchange loss | 146 | 148 | 51 |
| Other expense, net | 4,677 | 2,448 | 2,500 |
| Earnings before income tax expense | 6,250 | 13,477 | 12,989 |
| Income tax expense | 1,377 | 1,632 | 1,440 |
| Net earnings | 4,873 | 11,845 | 11,549 |
| Net earnings attributable to noncontrolling interest | 10 | 9 | 7 |
| Net earnings attributable to AbbVie Inc. | $4,863 | $11,836 | $11,542 |
| Per share data | |||
| Basic earnings per share attributable to AbbVie Inc. | $2.73 | $6.65 | $6.48 |
| Diluted earnings per share attributable to AbbVie Inc. | $2.72 | $6.63 | $6.45 |
| Weighted-average basic shares outstanding | 1,768 | 1,771 | 1,770 |
| Weighted-average diluted shares outstanding | 1,773 | 1,778 | 1,777 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.